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and perhaps satisfaction for either the 
patient or the provider can be improved 
with rapid diagnosis of AKI, which also 
would prove to be helpful. For example, 
should dipsticks be given to patients to 
monitor contrast nephropathy, or to 
monitor analgesic nephropathy from 
nonsteroidal anti-in1 ammatory drugs 
during pain crisis? Financial outcomes 
may be precisely quantified, and cost 
saving may be achieved by early dis-
charge with home monitoring for AKI 
using dipsticks. Patient, provider, and 
3 nancial outcomes need to be studied 
further in the setting of AKI and incor-
porated within the clinical studies of 
newer diagnostic tests. 
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 Regardless of  the underlying etiology, 
chronic kidney disease (CKD) is character-
ized by progressive 3 brosis and sclerosis 
that ultimately aE ect all substructures of the 
kidney. Epidemiologic studies have identi-
3 ed several variables that can predict CKD 
outcomes and may therefore be considered 
risk factors for CKD progression.  ese fac-
tors include African-American race, pro-
teinuria, high blood pressure, high dietary 
protein intake, obesity, anemia, dyslipi-
demia, and smoking. In comparison with 
whites, African Americans and Native 
Americans have 3.6 and 1.8 times higher 
incidences of end-stage renal disease 
(ESRD), respectively. 1 Furthermore, 
 African-American race was independently 
associated with a greater rate of decline in 
glomerular 3 ltration rate in the Modi3 ca-
tion of Diet in Renal Disease Study. 2  e 
incident rate of ESRD in the Hispanic pop-
ulation is 1.5 times greater than that in non-
Hispanics. 1 Although mechanisms 
underlying such racial diE erences remain 
to be elucidated, possible explanations 
include an increased prevalence of diabetes 
mellitus, lower nephron number, increased 
susceptibility to salt-sensitive hypertension, 
yet- undiscovered genetic factors, and dif-
ferences in environment, lifestyle, and 
socioeconomic status. 3 
 Identifying treatable risk factors for CKD 
in African Americans has the potential to 
reduce the excess burden of ESRD in this 
population. Because renal 3 brosis is associ-
ated with CKD progression and transform-
ing growth factor-  1 (TGF-  1) likely 
facilitates this 3 brosis, Suthanthiran and col-
leagues explored the hypothesis that TGF-
  1 overexpression occurs more frequently 
in African Americans with ESRD than in 
whites suE ering from the same disease.  is 
group has previously reported that  African 
Americans with hypertension and ESRD 
exhibit higher circulating levels of TGF-  1 
when compared with whites. 4 – 6 In this issue 
of  Kidney  International , 7 Suthanthiran and 
colleagues dig a little bit deeper, using a 
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 Circulating TGF-  1 as a reliable 
biomarker for chronic kidney 
disease progression in the 
African-American population 
 Soo Bong  Lee 1 ,  Keizo  Kanasaki 1 and  Raghu  Kalluri 1 , 2 , 3 
 Progressive renal  fibrosis is common to all chronic kidney diseases 
(CKD). Suthanthiran and colleagues identified a positive association 
between transforming growth factor-  1 and several risk factors for CKD 
progression in African Americans but not in whites . This study offers a 
possible explanation for the higher prevalence of end-stage renal 
disease in African Americans and highlights the need for a better 
therapeutic strategy for this population. 
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cross-sectional study to further examine the 
impact of TGF-  1 on ESRD. 
 TGF-  1 is a well-studied pro3 brogenic 
cytokine that likely plays an important role 
in the process of CKD progression, and 
blockade of this cytokine in experimental 
models prevents progression of CKD. 8 – 10 
The role of the renin – angiotensin – aldo-
sterone system (RAAS) in the progression of 
CKD has also been the focus of much inves-
tigation. Many experimental studies have 
shown bidirectional activities of TGF-  and 
the RAAS: renin or angiotensin II induces 
TGF-  activation, 11,12 and TGF-  1 also 
stimulates angiotensin II. 13,14 
 Suthanthiran and colleagues 7 report a 
positive association between the circulating 
concentration of TGF-  1 and a variety of 
established risk factors for CKD progression 
( Figure 1 ). Peripheral blood TGF-  1 protein 
levels are positively associated with plasma 
renin activity (PRA), systolic blood pres-
sure, diastolic blood pressure, body mass 
index (BMI), and the presence of metabolic 
syndrome in African Americans but not in 
whites. TGF-  1 protein levels are also pre-
dictive of microalbuminuria in  African 
Americans when compared with whites. 
 ese results suggest that TGF-  1 may con-
tribute to renal disease progression by mod-
ulating multiple risk factors more robustly 
in African Americans. Such different 
degrees of association between TGF-  1 and 
risk factors for CKD in African Americans 
and whites may explain the greater  incidence 
of ESRD in African Americans. 
  e new report by Suthanthiran and col-
leagues 7 is the 3 rst clinical study demon-
strating a positive relationship between 
TGF-  1 and the RAAS in humans. It is now 
well established that inhibition of the RAAS 
with angiotensin-converting enzyme inhib-
itors (ACEIs) and / or AT 1 receptor blockers 
(ARBs) has a bene3 cial eE ect on several 
disease categories, such as hypertension 
with or without end organ damage and pro-
gressive CKD, and that it is eE ective in pre-
venting and treating diabetic nephropathy. 
 Although the cross-sectional nature of 
this study limits the ability to infer a causal 
relationship between TGF-  1 and the 
RAAS, the observed positive association 
and its limitation to African Americans 
are important. A well-designed cohort 
study could provide more clear evidence 
in the future and allow for further build-
ing on this provocative 3 nding. 
 Both RAAS inhibitors, ACEIs and ARBs, 
have been shown to reduce the  production 
of TGF-  1 in experimental rodent mod-
els 15,16 and in humans with CKD. 17 In a 
prospective study of renal-transplant recipi-
ents, treatment with typical antihypertensive 
doses of the ARB losartan decreased plasma 
levels of TGF-  1 within 2 weeks. 17 Is it pos-
sible to infer from this evidence that inhibit-
ing the RAAS in African Americans with 
CKD will prevent or slow the progression of 
their renal dysfunction by suppressing 
TGF-  1 production? The answer to this 
question is not a simple  ‘ yes. ’ As Suthanthiran 
and colleagues 7 point out, African  Americans 
tend to exhibit salt volume – dependent 
hypertension with a lower level of PRA, and 
they show a lower sensitivity to RAAS inhib-
itors when  compared with whites. 18 Further-
more, a recent multicenter cohort study 
revealed that most African Americans with 
hypertensive CKD treated with RAAS inhib-
itors continued to exhibit disease progression 
in the long term. 19  ese 3 ndings suggest 
that RAAS inhibitors may not eE ectively 
reduce TGF-  1 in the African-American 
population. In this regard, it would be inter-
esting to investigate whether there is an asso-
ciation between TGF-  1 and the various risk 
factors for CKD and how the eE ect of RAAS 
inhibitors on CKD progression is a function 
of PRA in the population with either lower 
or higher PRA, independent of race. 
 Previous studies have shown that RAAS 
inhibitors can reduce TGF-  1 levels by a 
maximum of about 50 – 60 % in experimen-
tal disease. 14,17 Unfortunately, the data for 
human disease remain limited.  e degree 
of TGF-  1 reduction in humans treated 
with an ACEI or an ARB remains unde-
termined . Can TGF-  1 levels be normal-
ized to baseline, or are they only marginally 
aE ected by ACEI or ARB treatment? At 
present, clinical trials are investigating the 
utility of anti-TGF-  antibodies in idio-
pathic pulmonary  3 brosis, focal segmental 
glomerulosclerosis, renal-cell carcinoma, 
and diabetic  nephropathy. 10 Anti-TGF-  
therapy may combine well with ACEIs or 
ARBs in human kidney diseases such as 
diabetic nephropathy and focal segmental 
glomerulosclerosis, especially in the 
 African-American population. 
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 Figure 1  |  Association between risk factors for CKD progression and circulating TGF- b 1 levels 
in the context of the renin – angiotensin – aldosterone system and the plasminogen activator 
inhibitor-1 system. This schematic highlights the positive association between TGF-  1 levels and 
plasma renin activity (PRA), systolic blood pressure (BP), diastolic BP, body mass index, metabolic 
syndrome, and microalbuminuria. The arrows denote stimulatory effects. Ang II, angiotensin II; 
PAI-1, plasminogen activator inhibitor-1. 
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 Knowledge of peritoneal anatomy and 
physiology is constantly being applied to 
how we prescribe and perform peritoneal 
dialysis (PD). Also important is the gen-
eral comprehension of how we implement 
this therapy. Mehrotra and colleagues 1 
(this issue) utilized the United States Renal 
Data System (USRDS) to describe how 
American nephrologists practice PD. 
Using the years 1996 – 1998 as a reference, 
they compared changes in PD practice in 
1999 – 2001 and 2002 – 2004.  eir 3 ndings 
regarding the cornucopia of material in 
the data set are just the tip of the iceberg. 
Quite probably, many more papers are in 
preparation from the present analyses, 
generously shared with us now to whet 
our appetite. 
 The theme of the work of Mehrotra 
 et al. 1 is the comparison of outcomes 
utilizing continuous ambulatory PD 
(CAPD) versus automated PD (APD). In 
short, outcomes were similar.  e initial 
question of CAPD versus APD outcomes 
arose because overall outcomes of PD 
improved, and simultaneously, the preva-
lence of APD rose over that of CAPD.  e 
authors sought to de3 ne or refute a cause 
and eE ect. What the authors have not dis-
cussed yet are the other practice variables 
that aE ect the utilization of CAPD versus 
APD in the United States. A drill down on 
the data may yield that fruit. 
 APD is slightly more expensive than 
CAPD, for several reasons. First, the cycler 
has to be purchased or leased. Second, in 
general, greater solution volumes are 
needed, albeit in larger, more cost-e  cient 
bags.  ird, cycler training plus manual 
training for APD takes longer than mere 
manual exchange training for CAPD. 
Lastly, the more expensive icodextrin 
solution is more likely to be used in APD 
for the long dwell than it is in CAPD ’ s long 
dwell. So if APD is more expensive than 
CAPD, why is it becoming more preva-
lent?  ere is more training revenue to the 
dialysis facility with the extended training 
required for APD.  is revenue exceeds 
that of monthly supervision fees. How-
ever, I do not think this is the driver of the 
popularity of APD. In my opinion, the 
answer is simple and, quite frankly, refutes 
the attacks on for-profit large dialysis 
organizations. Patients prefer it, and pro-
viders accommodate patient preferences 
at the potential expense of pro3 t margins 
(lost because of the use of more 1 uids). 
 At the start of the observation period of 
Mehrotra  et al. 1 (1996 – 1998), most 
 American PD programs were training 
patients for just CAPD.  en, toward the 
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 Learning about the practice 
of peritoneal dialysis 
 Thomas A.  Golper 1 
 Observational studies are valuable  and provocative. We are learning 
about how we practice peritoneal dialysis (PD) and how we might 
improve on that practice. For example, outcomes of PD  therapy are not 
worse in large patients. Perhaps this will encourage physicians and 
patients to utilize PD in large patients. In addition, better descriptions of 
how we practice will help to identify systematic barriers to the 
advancement of home dialysis. 
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